$PRME

$4.35 +$0.74 (20.5%) Close

$PRME Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 181.4M shares outstanding

Who owns PRME?

By type of holder

Institutions 58.4% Insiders 41.6% Everyone else 0.0%

Concentration Top 10 holders own 102.9%

Liu David R. 11.2% · Robert Nelsen 10.3%

Institutional ownership

58.4%

+4.1 pts vs last qtr

Institutional holders

186

-6 vs last qtr

Net shares bought

+7.4M

by institutions in Q2 2026

New / sold out

22 / 28

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Goldman Sachs Group Inc +2.5M
ARK Investment Management LLC +2.1M

Biggest sellers in Q2 2026

D. E. Shaw & Co., Inc. −744.7K
Susquehanna International Group, LLP SOLD OUT −715.8K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Prime Medicine, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+63.5%

+27.88% a year

Each share's claim on the business

−38.8%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $69.2M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years67% 1–3 years16% Under 1 year17%

Quarterly turnover

10.2%

of institutional shares changed hands

Top 10 managers, median time held

3.5 years

Super Investors

Investment managers reporting PRME on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
A Alphabet Inc.	16.6M	9.13%	Unchanged	2022	0.1%
Shares held by quarter Peak holding16.6M (Q3'25) Change over 8 quarters+1.5M Share of the company9.130% Alphabet Inc.'s full portfolio →
B BlackRock, Inc.	9.6M	5.29%	+1.1M (+12.9%)	2022	0.0%
Shares held by quarter Peak holding9.6M (Q2'26) Change over 8 quarters+4.3M Share of the company5.290% BlackRock, Inc.'s full portfolio →

Alphabet Inc.

16.6M

% of company

9.13%

Change vs last qtr

Unchanged

Held since

2022

BlackRock, Inc.

9.6M

% of company

5.29%

Change vs last qtr

+1.1M (+12.9%)

Held since

2022

28 more super investors behind a free account

See every manager holding Prime Medicine, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting PRME on Form N-PORT; together they hold 20.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
AG ARK Genomic Revolution ETF ARK ETF Trust	$21.9M	7.5M	4.14%	1.41%	July 31, 2026
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$19.3M	5.2M	2.88%	0.18%	June 30, 2026

ARK Genomic Revolution ETF

ARK ETF Trust

Position value

$21.9M

% of company

4.14%

% of the fund

1.41%

As of

July 31, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$19.3M

% of company

2.88%

% of the fund

0.18%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Prime Medicine, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
LD Liu David R. Insider	20.2M	11.16%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company11.160% Liu David R.'s insider activity →
RN Robert Nelsen 5%+ holder 13D · 10.4%	18.6M	10.25%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.250% Disclosed stake13D · 10.4% View the 13D/G filing →

Liu David R.

Insider

20.2M

% of company

11.16%

Change vs last qtr

—

Held since

—

Robert Nelsen

5%+ holder13D · 10.4%

18.6M

% of company

10.25%

Change vs last qtr

—

Held since

—

14 more holders behind a free account

See every insider and 5%+ holder of Prime Medicine, Inc..

Comments